Forum Financial Management LP Raises Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Forum Financial Management LP boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 56.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,509 shares of the medical equipment provider’s stock after buying an additional 1,273 shares during the period. Forum Financial Management LP’s holdings in Zimmer Biomet were worth $371,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Dodge & Cox raised its stake in Zimmer Biomet by 12.0% in the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider’s stock valued at $2,019,480,000 after purchasing an additional 2,044,645 shares during the last quarter. Van ECK Associates Corp raised its position in shares of Zimmer Biomet by 5.9% in the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock valued at $417,814,000 after buying an additional 218,688 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Zimmer Biomet by 398.7% in the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider’s stock worth $369,469,000 after buying an additional 2,796,372 shares in the last quarter. Norges Bank acquired a new position in Zimmer Biomet during the fourth quarter worth about $216,223,000. Finally, FMR LLC grew its stake in Zimmer Biomet by 91.6% during the 4th quarter. FMR LLC now owns 1,438,011 shares of the medical equipment provider’s stock valued at $151,897,000 after acquiring an additional 687,675 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.95% of the stock is currently owned by company insiders.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $97.90 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock has a market capitalization of $19.37 billion, a price-to-earnings ratio of 22.00, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. The business has a 50-day moving average of $105.92 and a 200 day moving average of $106.74. Zimmer Biomet Holdings, Inc. has a 12 month low of $96.58 and a 12 month high of $123.96.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the company earned $2.20 earnings per share. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.98%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s payout ratio is currently 21.57%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Barclays lowered their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. BTIG Research reissued a “buy” rating on shares of Zimmer Biomet in a research note on Monday, April 14th. JMP Securities reaffirmed a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Finally, Royal Bank of Canada cut their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.